April 2015

New Product - Xeljanz

Xeljanz (tofacitinib (as citrate)) is a selective inhibitor of the Janus kinase (JAK) family of kinases with a high degree of selectivity against other kinases in the human genome. In kinase assays, tofacitinib inhibits JAK1, JAK2, JAK3, and to a lesser extent tyrosine kinase 2 (TyK2). Treatment with tofacitinib was associated with dose dependent reductions of circulating CD16/56+ natural killer cells, with estimated maximum reductions occurring at approximately 8‑10 weeks after initiation of therapy. Xeljanz is indicated for the treatment of the signs and symptoms of moderate to severe active rheumatoid arthritis in adults who have had an inadequate response or are intolerant to methotrexate. Xeljanz can be used alone or in combination with nonbiological DMARDs, including methotrexate. Therapy with Xeljanz should be initiated and monitored by a rheumatologist or specialist physician with expertise in the management of rheumatoid arthritis. Xeljanz must not be used in combination with biological DMARDs or other potent immunosuppressive agents such as azathioprine and cyclosporin. Xeljanz should not be used in patients with severe hepatic impairment. Xeljanz 5 mg tablets are available in blisters of 14’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629